Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury
about
Prostaglandin E Receptor Subtype 4 Signaling in the Heart: Role in Ischemia/Reperfusion Injury and Cardiac HypertrophyThe contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failureE-type prostanoid receptor 4 (EP4) in disease and therapyThe Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin SensitivityAn Update of Microsomal Prostaglandin E Synthase-1 and PGE2 Receptors in Cardiovascular Health and DiseasesGene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice.Inhibition of EP4 signaling attenuates aortic aneurysm formationLack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions.Understanding the role of prostaglandin E2 in regulating human platelet activity in health and diseaseDeletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation.Gaseous hydrogen sulfide protects against myocardial ischemia-reperfusion injury in mice partially independent from hypometabolismActivation of prostaglandin E2-EP4 signaling reduces chemokine production in adipose tissue.Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation.Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis and modulation of autophagyTryptase activates isolated adult cardiac fibroblasts via protease activated receptor-2 (PAR-2).Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.Prostaglandin E2 reduces swine myocardial ischemia reperfusion injury via increased endothelial nitric oxide synthase and vascular endothelial growth factor expression levels.Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases.A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart.Pharmacology of Ischemia-Reperfusion. Translational Research Considerations.Treatment with cardiotonic pills(®) after ischemia-reperfusion ameliorates myocardial fibrosis in rats.Heart failure-induced activation of phospholipase iPLA2γ generates hydroxyeicosatetraenoic acids opening the mitochondrial permeability transition pore.Prostanoid EP4 Agonist L-902,688 Activates PPARγ and Attenuates Pulmonary Arterial Hypertension.Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction.EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.Knockout of the Prostaglandin E2 Receptor Subtype 3 Promotes Eccentric Cardiac Hypertrophy and Fibrosis in Mice.EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension.Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE (Prostaglandin E) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury
P2860
Q26748618-B11D0004-B003-4D9F-A4E1-8132EB9FF9C0Q26830372-33436D3B-7D36-4CF6-BB18-F59301AC91DAQ26851156-D4567490-484C-4807-A88D-65E08EBFAA24Q27322096-3923384B-E65B-44F0-9BB6-8BE66D909C91Q28067884-9C99AB5F-4944-4936-B412-31C281562233Q33656036-E71C4027-637C-4A25-B4AD-61E4472F87CCQ34263414-E7C2BFE1-E0CB-41F0-B2DF-3622C5E85BF8Q34410269-591FFD7D-938B-44BC-8CA0-1712CB7711C5Q34480894-1683CCC7-E1B0-4945-93BF-087D2900F13DQ34514569-20299A18-EE56-4A3D-BD9E-B2499239142CQ34722817-B44096E5-C26D-423A-8DDF-D55DF58BB2FDQ35014273-15A67C11-F502-4E6F-B3B9-552C5D80DADBQ35128063-883BFFBC-090A-4591-A1C1-E3C3E44B2AADQ35138227-ED23220C-D882-49FE-97C7-7B428220E661Q35730075-4E466ED5-058E-4F4F-A390-C8937D04CB13Q37688473-F9594658-4B57-4DF3-B9F0-B517A0A13CA0Q37701229-C405D928-ACE5-45F5-B203-678446F55354Q37893433-FB09A559-20BD-4515-91C2-C6FF9979CBFEQ38364525-9137A6C5-F797-4CC0-850C-50F199FECF81Q38842544-91DF014E-4AD8-417F-8A59-5439C0221299Q44748423-5F7F5CC9-594E-41F5-B771-C8DDDA9492AAQ47381689-6A1302DC-139D-4190-8CA2-3A36F854A845Q47394239-C10A443D-4F2B-4B83-831A-D194DE2D7CDFQ51742158-0044CD24-903F-43A2-9177-5010C14BAA9CQ53176610-4EEDAEF5-AD9B-4220-90A9-1A6AEF1BC012Q54199502-760F4120-289B-4118-98AE-C8FCC6B79F31Q54935988-E4163F93-3CB9-43DC-BAAC-D638F4A90BCCQ59124551-015793C6-69A2-48EF-8058-68B1C8B7F9DC
P2860
Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological activation of ...... l ischaemia/reperfusion injury
@en
Pharmacological activation of ...... ischaemia/reperfusion injury.
@nl
type
label
Pharmacological activation of ...... l ischaemia/reperfusion injury
@en
Pharmacological activation of ...... ischaemia/reperfusion injury.
@nl
prefLabel
Pharmacological activation of ...... l ischaemia/reperfusion injury
@en
Pharmacological activation of ...... ischaemia/reperfusion injury.
@nl
P2093
P2860
P356
P1476
Pharmacological activation of ...... l ischaemia/reperfusion injury
@en
P2093
Jun-ichi Suzuki
Kazuya Isobe
Keiichi Hishikari
Kiyoshi Takayama
Masahito Ogawa
Michihito Onishi
Mitsuaki Isobe
Teisuke Takahashi
P2860
P304
P356
10.1093/CVR/CVN254
P577
2008-09-18T00:00:00Z